M&A

News

BioMarin takes a leap towards its $4bn revenue target with a $4.8bn deal to acquire Amicus, which has two rare disease therapies on the market.

News

Sobi has hit the acquisition trail with a deal to buy Arthrosi Therapeutics for up to $1.5 billion, adding a drug in late-stage testing for gout.

News

Swiss biotech Veraxa's listing on the Nasdaq, delayed by the record 43-day US government shutdown, should now complete in the first quarter of 2026.

Digital

Rob Milnes (Ultrahuman) connected with pharmaphorum off the Frontiers Health stage to share some insights.

News

Lundbeck won't raise its offer to buy Avadel any further, clearing the way for the sleep disorder specialist to complete a merger with Alkermes.

News

Alkermes has been forced to raise its offer for narcolepsy drug developer Avadel Pharma, after a rival bid from Lundbeck was deemed superior.